Daiichi Sankyo And GSK Build Japanese Vaccine Firm, While Takeda Expands Abroad
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Daiichi Sankyo and Takeda claim to have a path for the top vaccine spot in Japan, but all vaccine firms seem poised to benefit from MHLW's more generous attitude toward preventative medicine.
You may also be interested in...
Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply
TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.